Conditions: Relapsed or Refractory Multiple Myeloma
Keywords: Cabozantinib (XL184) 12-240
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 11
Healthy volunteers: no

Brief summary:
This study is an open label phase I/II trial to investigate the safety and efficacy of Cabozantinib for patients with relapsed or refractory myeloma.

Detailed description:

Arms:
arm 1: Eligible patients will receive cabozantinib as a tablet, orally daily. One cycle is defined as 28 days. Myeloma response will be assessed by IMWG criteria after each cycle. The DLT evaluation period will be six weeks. This trial will be a standard 3 by 3 dose escalation design, where three daily dose levels (20mg, 40mg, and 60mg) will be investigated.

Interventions: intervention 1: Cabozantinib (XL184)
Intervention descriptions: intervention 1: None

Protocol document: